

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)



ATHENS MEDICAL CENTER S.A.

**INTERIM FINANCIAL STATEMENTS
FOR THE NINE MONTH PERIOD OF 2005**

**IN ACCORDANCE WITH THE INTERNATIONAL FINANCIAL
REPORTING STANDARDS (IFRS)**

It is certified that the accompanying interim Financial Statements are those approved by the board of directors of “ATHENS MEDICAL S.A.” in November 26th 2005 and they are uploaded to the internet address: www.iatriko.gr. The published records and information, aim at providing the reader some general financial records and information, but they do not provide the whole picture of the financial condition and the results of the Company, according to the International Accounting Standards and the International Financial Reporting Standards.

Georgios Apostolopoulos
President of the Board of Directors
ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

INDEX TO INTERIM FINANCIAL STATEMENTS

	<u>PAGE</u>
Statements of income for the nine month period ended in 30 th September 2005 and 2004	3
Balance sheets as of 30 th September 2005 and 31 st December 2004	4-5
Statement of changes in Equity for the nine month period ended in 30 th September 2005	6
Statement of changes in Equity for the nine month period ended in 30 th September 2004	7
Statements of Cash Flow for the nine month period ended in 30 th September 2005 and 2004	8
Notes to the Interim Financial Statements	9-40
Appendix I – Reconciliation of Shareholder Equity in 1 st January 2005 and in 1 st January 2004, as well as of the Results for the Period ended in 30 th September 2004	41-55
Appendix – Subsidiaries of ATHENS MEDICAL CENTER S.A.	56
Appendix IV – Tax unaudited years per Company	56



ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005
 (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

INCOME STATEMENT
FOR THE PERIOD ENDED IN 30 SEPTEMBER 2005 AND 2004
 (All amounts are presented in thousands of Euro)

		The Group				The Company			
	Notes	30 September 2005	30 September 2004	Q3 2005	Q3 2004	30 September 2005	30 September 2004	Q3 2005	Q3 2004
INCOME:									
Revenue		155.716	137.726	47.477	42.526	149.937	133.462	45.767	41.100
Cost of sales		(123.602)	(108.525)	(39.611)	(35.948)	(125.081)	(109.508)	(40.148)	(36.288)
Gross Profit		32.114	29.202	7.867	6.578	24.856	23.954	5.619	4.812
Administrative expenses and Distribution Costs	6	(17.374)	(16.976)	(5.845)	(5.074)	(15.623)	(15.601)	(4.999)	(4.751)
Other income/ (expenses)	7	1.544	1.650	407	688	1.529	1.630	393	675
Net financial income/ (costs)	8	(3.443)	(3.997)	(1.141)	(1.560)	(2.079)	(2.996)	(1.071)	(1.526)
		12.842	9.878	1.287	632	8.683	6.987	(58)	(790)
PROFIT BEFORE TAX		0	0						
Income Tax Expense	9	(4.003)	(3.607)	(570)	(257)	(2.165)	(2.111)	393	611
PROFIT FOR THE PERIOD		8.838	6.271	716	376	6.518	4.876	335	(179)
Attributable to:									
Equity holders of the parent company		7.053	5.132	255	(71)	6.518	4.876	335	(179)
Minority Interest		1.786	1.139	461	447				
		8.838	6.271	716	376	6.518	4.876	335	(179)
Earnings per Share (in Euro)									
Basic	10	0,08	0,06	0,00	0,00	0,08	0,06	0,00	0,00

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

BALANCE SHEET

30 SEPTEMBER 2005 AND 31 DECEMBER
2004

(All amounts are presented in thousands of Euro)

	Notes	The Group		The Company	
		30 September 2005	31 December 2004	30 September 2005	31 December 2004
ASSETS					
Non current assets					
Property, plant and equipment	11	278.130	283.818	252.953	257.174
Goodwill		1.979			
Other intangible assets	12	404	409	404	409
Investments in subsidiaries	13			13.586	11.167
Investments in associates consolidated by the equity method	14				
Guarantees		327	300	323	295
Deferred tax assets	9	7.291	8.272	7.205	8.128
Total non current assets		288.131	292.799	274.471	277.174
Current Assets:					
Inventories	15	4.889	5.387	4.701	5.126
Trade accounts receivable	16	82.066	70.328	80.549	69.418
Prepayments and other receivables	17	13.722	10.118	15.921	13.939
Financial assets at fair value through income statement		1	1		
Cash and cash equivalents	18	5.108	7.026	4.139	6.406
Total current assets		105.785	92.860	105.310	94.889
TOTAL ASSETS		393.916	385.659	379.781	372.063
EQUITY AND LIABILITIES					
Equity attributable to equity holders of the parent company					
Share capital	19	26.036	26.036	26.036	26.036
Share premium	19	15.267	15.267	15.267	15.267
Retained Earnings		39.565	35.032	31.649	27.651
Legal, tax free and special reserves	20	74.095	74.028	73.767	73.767
		154.963	150.363	146.719	142.721
Minority Interest		5.219	5.078		
Total equity		160.182	155.440	146.719	142.721

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Non-current liabilities:

Long term loans/borrowings	21	66.681	80.505	66.125	80.505
Government Grants	22	74	74	73	73
Deferred tax Liabilities	9	18.835	17.608	16.170	14.927
Provision for retirement indemnities	23	9.768	8.781	9.768	8.781
Deferred income		4.638	5.072	4.637	5.013

Total non-current liabilities		99.997	112.040	96.773	109.300
--------------------------------------	--	---------------	----------------	---------------	----------------

Current liabilities:

Trade accounts payable	24	69.173	55.936	75.859	61.947
Accrued and other current liabilities	25	7.762	13.635	7.096	12.546
Short term loans/borrowings	21	52.905	41.924	52.146	41.224
Current tax payable		3.897	6.684	1.187	4.326

Total current liabilities		133.738	118.179	136.288	120.043
----------------------------------	--	----------------	----------------	----------------	----------------

TOTAL EQUITY AND LIABILITIES		393.916	385.659	379.780	372.063
-------------------------------------	--	----------------	----------------	----------------	----------------



ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005
 (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY

30 SEPTEMBER 2005

	The Group					Minority Interest	Total Equity
	Attributable to equity holders of the parent company						
	Share capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total		
Balance, 1 January 2005	26.036	15.267	74.028	35.032	150.362	5.078	155.440
Period's profits				7.053	7.053	1.786	8.838
Exchange Differences			67		67		67
Buyout of Minority interest						(440)	(440)
Dividend of year 2004				(2.520)	(2.520)	(1.204)	(3.724)
Balance, 30 September 2005	26.036	15.267	74.095	39.565	154.963	5.219	160.182
	The Company						
	Share capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total Equity		
Balance, 1 January 2005	26.036	15.267	73.767	27.651	142.721		
Period's profits				6.518	6.518		
Dividends				(2.520)	(2.520)		
Balance, 30 September 2005	26.036	15.267	73.767	31.649	146.719		



ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY
30 SEPTEMBER 2004

	The Group					Minority Interest	Total Equity
	Attributable to equity holders of the parent company						
	Share Capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total		
Balance, 1 January 2004	26.036	15.267	69.186	28.090	138.579	4.351	142.930
Period's profits				5.132	5.132	1.139	6.271
Dividends						(443)	(443)
Other movements			817	(551)	266		266
Balance, 30 September 2004	26.036	15.267	70.003	32.671	143.977	5.047	149.024
	The Company						
	Attributable to equity holders of the parent company						
	Share Capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total		
Balance, 1 January 2004	26.036	15.267	69.085	21.996	132.384		
Period's profits				4.876	4.876		
Dividends							
Other movements			817	(573)	244		
Balance, 30 September 2004	26.036	15.267	69.902	26.299	137.504		

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CASH FLOW
FOR THE PERIOD ENDED IN 30 SEPTEMBER 2005

	The Group		The Company	
	30 September 2005	30 September 2004	30 September 2005	30 September 2004
Cash flows from operating activities				
Period's profit before taxation	12.842	9.878	8.683	6.987
<i>Adjustments for:</i>				
Depreciation	8.030	7.597	7.737	7.397
Gains/ (losses) due to fixed asset sale	40		(376)	
Depreciation of government grants		(26)		(26)
Provision for retirement indemnities (net amount)	987	1.085	987	1.085
Allowance for doubtful accounts receivable				
Financial income	(497)	(33)	(1.791)	(971)
Interest and other financial expenses	3.940	4.030	3.870	3.967
Other provisions	(24)	(28)		
Exchange differences of overseas subsidiaries consolidation	(58)	(38)		
Operational profit before changes in working capital variations	25.259	22.466	19.110	18.439
Increase/ (Decrease) in:				
Inventories	499	(36)	426	(32)
Short and long term accounts receivable	(18.157)	(7.490)	(13.113)	(8.752)
Increase/ (Decrease) in:				
Short and long term liabilities	15.124	2.180	13.716	3.553
Interest charges and related expenses paid	(3.940)	(4.030)	(3.870)	(3.967)
Paid taxes	(4.131)	(2.617)	(2.682)	(2.502)
Net Cash from operating activities	14.656	10.472	13.587	6.740
Cash flows from investing activities:				
Purchase of tangible and intangible fixed assets	(4.612)	(5.319)	(3.511)	(4.292)
Sale of tangible assets	2.011			
Acquisition of subsidiary	(2.418)		(2.418)	
Interest and related income received	67	27	46	15
Received dividends from subsidiaries	55	6	1.369	955
Sale of long term investments	376	249	376	250
Net Cash flows used in investing activities	(4.522)	(5.036)	(4.138)	(3.072)
Cash flows from financing activities				
Proceeds from debt/borrowings	6.033	60	5.418	484
Long term debt/borrowings repayment	(11.411)	(1.850)	(11.411)	(1.850)
Payment of finance lease liabilities	(3.203)	(3.174)	(3.203)	(2.934)
Dividends paid	(3.471)	(778)	(2.520)	
Net Cash flows used in financing activities	(12.052)	(5.743)	(11.716)	(4.301)
Net increase/ in cash and cash equivalents	(1.918)	(307)	(2.267)	(633)
Cash and cash equivalents at the beginning of the year	7.026	6.714	6.406	6.184
Cash and cash equivalents at the end of the year	5.108	6.407	4.139	5.551



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(a) **CORPORATE INFORMATION:**

The Company “ATHENS MEDICAL SOCIETE ANONYME” with the distinctive title “ATHENS MEDICAL CENTER S.A.” (hereafter the “Company” or the “Parent Company”) and its subsidiaries (hereafter the “Group”) are involved in the area of health care services with the organization and operation of hospital units. The Company’s and the Group’s head offices are located in the Municipality of Amarousion Attica in 5-7 Distomou Street and employ 2.578 and 2.746 employees respectively.

The Company’s shares are publicly traded on the Athens Stock Exchange.

The financial statements of the Company and the Group, for the period ended in 30 September 2005, were approved for issuing, by the decision of the Board of Directors in 26 November 2005.

The subsidiaries, which were included in the accompanying consolidated financial statements of the Group, are described in Appendix II.

(b) **PREPARATION BASE OF FINANCIAL STATEMENTS:**

(a) **Preparation Base of Financial Statements:** The accompanying interim financial statements of the Group and the Company (hereafter financial statements) have been prepared under the historical cost convention, except the land and the buildings, which at the date of transition to International Financial Reporting Standards (1st January 2004) were valued at their fair value and this fair value was used as deemed cost at the above date. As more fully discussed in Note 2 (c), the accompanying financial statements have been prepared in accordance to IFRS for the first time, by applying IFRS 1 “First-time Adoption of International Financial Reporting Standards” with the transition date being the 1st of January 2004.

(b) **Statutory Financial Statements:** The Company and its domestic (Greek) subsidiaries maintain their accounting books and prepare financial statements in accordance to the Greek Company Law 2190/1920 and the applicable tax legislation. The foreign subsidiaries of the Company maintain their accounting records and prepare financial statements in accordance to the applicable laws and regulations of the countries in which they operate. For the preparation of the consolidated financial statements of the parent company, the financial statements of the foreign subsidiaries are adjusted in accordance to the provisions of the Greek Company Law 2190/1920. The accompanying consolidated financial statements have been based on the above-mentioned statutory consolidated financial statements appropriately adjusted and reclassified by certain out-of-book adjustments in order to comply with IFRS.

The principle out-of-book entries recorded for IFRS purposes on the equity of the 1st of January 2004 and the 31st of December 2004 are presented in Appendix I.

(c) **First Time Adoption of International Financial Reporting Standards:** Pursuant to EU regulation 1606/2002 and according to Law 3229/04 (as amended by law 3301/04) Greek Companies listed on any Stock Exchange (foreign or domestic) are required to prepare their statutory financial statements from fiscal years beginning on January 1, 2005, onwards, in accordance to IFRS. Based on the provisions of IFRS 1 and the above-mentioned Greek legislation, such entities are obliged to report at least one year of comparative financial Statements (31 of December 2004) under IFRS.

Therefore, the majority of companies adopting the IFRS for the first time, as mentioned above, will have the 31st of December 2005 as a financial statement date, and the 1st of January 2004 as a transition date,. The Company intends to prepare and publish its first full year IFRS financial statements, within the statutory time framework and the reporting date of the above financial statements will be December 31, 2005.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The accompanying financial statements 2004 have been prepared based on estimations of the management concerning the IFRS, which will be effective on the first reporting date (31 of December 2005) and consequently they are by nature preparatory/ tentative.

The Company applied the IFRS 1 Rule “First Time Adoption of IFRS ” in the preparation of the accompanying financial statements. Based on the respective provisions of IFRS 1, the following exceptions were adopted:

- The Company decided not to apply IFRS 3 “Business Combinations” retrospectively, to business combinations, which occurred prior to the transition date to IFRS (1st of January 2004).

Consequently, and according to IFRS 1, regarding past business combinations the Company:

- (i) Maintained the same classification as in its previous Greek accounting standards (GAS) financial statements.
- (ii) Recognized all assets and liabilities at the transition date to IFRS, which were acquired or assumed in business combinations except from:
 - Certain financial assets and financial liabilities that were not under previous GAS, and
 - Assets, including goodwill, and liabilities that were not recognized in the Company's consolidated balance sheet under previous GAS and would also not qualify for recognition under IFRS in the separate balance sheet of the acquiree.
- (iii) Excluded/wrote off from its opening IFRS consolidated balance sheet any item recognized under previous GAS that does not qualify for recognition as an asset or liability under IFRS.

At the transition date to IFRS, the Company tested the carrying amount of goodwill under previous GAS for impairment, based on the provisions of IAS 36 “Impairment of Assets” and the resulting impairment losses, were recognized in retained earnings as of the above date. The impairment tests were based on the conditions that existed at the transition date to IFRS.

- The Company decided to evaluate its land and buildings on the transition date to IFRS at their fair value and used those fair values as deemed cost at that specific date.
- Concerning the provision for retirement indemnities all cumulative actuarial gains and losses were recognized at the transition date to IFRS, while the corridor approach was used for the actuarial gains and losses which were incurred during 2004 . This exemption was used for all relevant plans existing at the transition date.
- The accumulated exchange rate differences that arose due to the currency conversion of balance sheets of the subsidiaries abroad were deemed to be zero at the date of transition to IFRS (they were included in the retained earnings) and the gain or loss on a subsequent sale/disposal of any subsidiary abroad will not include exchange differences that arose before the transition date to IFRS and will include every subsequent exchange difference.
- The Company’s estimates under IFRS at the date of transition to the IFRS were consistent with the estimates that took place for the same date under previous GAS (after adjustments to reflect any difference in the accounting policies), unless there was objective evidence that these estimates were wrong.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

- The assets and liabilities of certain foreign subsidiaries that had not adopted the IFRS standards prior to the parent company, have been included in the accompanying consolidated financial statements at the same carrying amounts as that reflected in their separate stand alone financial statements after consolidation and adjustment entries and equity adjustments.

(d) Effect of newly published accounting Standards (IFRS or IAS) and Interpretations (SIC):

The Company, as provided by IAS 39, applied IAS 32 “Financial Instruments: Disclosure and Presentation” (revised in 2003) and IAS 39 “Financial Instruments: Recognition and Measurement” (Revised in 2003) from the 1st of January 2005.

At the 18th of December 2003 revisions were published concerning:

- IAS 1 “Presentation of Financial Statements”,
- IAS 2 “Inventories”,
- IAS 8 “Accounting Policies, Changes in Accounting Estimates and Errors”,
- IAS 10 “Events after the Balance Sheet Date”,
- IAS 16 “Property, Plant and Equipment”,
- IAS 17 “Leases”,
- IAS 21 “The Effects of Changes in Foreign Exchange Rates”,
- IAS 24 “Related party Disclosures”,
- IAS 27 “Consolidated and Separate Financial Statements”,
- IAS 28 “Investments in Associates”,
- IAS 31 “Interests in Joint-Ventures”,
- IAS 33 “Earnings per Share”,
- IAS 40 “Investment Property”.

The adoption date of all the revised standards is the 1st of January 2005, while previous adoption is encouraged. The revised standards replace, as well, the below-mentioned Interpretations which are withdrawn:

- SIC 1 “Consequence - Different types of inventory cost accounting”,
- SIC 2 “Consequence - Capitalization of Borrowing Cost”,
- SIC 3 “Deletion of unrecognized gains or losses from Transactions with Associates”,
- SIC 5 “Classification of Financial Instruments - Provisions for Possible Arrangement”,
- SIC 6 “Existing Software Modification Cost”,
- SIC 11 “Foreign Exchange – Capitalization of Losses arising from Significant FX Devaluations”,
- SIC 14 “Tangible Assets – Hedging for Impairment or elements’ Loss”,
- SIC 16 “Equity – Purchase of own Shares ”,
- SIC 17 “Equity – Equity Transaction Costs”,
- SIC 18 “Consequence – Alternative Methods”,
- SIC 19 “Presentation Currency – Presentation and Valuation of the Financial Statements under IAS 21 and IAS 29”,
- SIC 20 “Equity Accounting – Loss Recognition”,
- SIC 23 “Tangible Assets – Significant Inspections or General Repairs”,
- SIC 24 “Earnings per share – Financial Instruments that can be arranged as Shares”,
- SIC 30 “Presentation Currency – Conversion from Valuation Currency to Presentation Currency”, and
- SIC 33 “Consolidation and Equity Method – Possible Voting Rights and Ownership Rights Allocation”.

**INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005**

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The IFRS 2 “Share-based Payments” (which replaced also particular Disclosure provisions of IAS 19 “Employee Benefits”) was issued in 19 February 2004. The IFRS 2 is valid for annual periods starting from 1st of January 2005. Previous application is encouraged. The 31st of March 2004 there were issued: IFRS 3 “Business Combinations” (which replaced the IAS 22 “Business Combinations”), IFRS 4 “Insurance Contracts” and IFRS 5 “Long-current Assets Held for Sale and Discontinued Operations” (which replaced IAS 35 “Discontinued Operations”). The 31st of March 2004 there were also issued revisions of IAS 36 “Impairment of Assets” and IAS 38 “Intangible Assets” and in both cases related to IFRS 3. IFRS 3 is adopted in all Business Combinations that took place from the 31st of March 2004 and afterwards. Special transitional regulations are applied in the previously recognized goodwill, negative goodwill, in intangible assets and investments that are recognized by the equity method. IFRS 5 must be adopted in annuals which start from the 1st of January 2005 and afterwards. Previous adoption is permitted, if the necessary information, in order for the standard to be adopted, were received by the time the relative Business Combinations were initially recognized. The revised IAS 36 and IAS 38 must be adopted for annual periods that start at or after the 31st of March 2004 (or the adoption date of IFRS 3 for goodwill and the intangible assets acquired in a Business Combination).

According to the respective regulations of IFRS 1, in the preparation of the first financial statements under IFRS, a company must adopt the IFRS that will be valid in the reporting date of the first financial statements, for all periods presented, as well as for the transition balance sheet. Therefore, since the date for the first, in full, company's financial statements under IFRS, will be the 31st of December 2005, all the revised or newly issued Standards mentioned above were used for the preparation of accompanying financial statements.

- (e) **Approval of Financial Statements:** The Board of Directors of Athens Medical S.A. approved the interim financial statements for the period ended on September 30, 2005, on November 26, 2005.
- (f) **Use of Estimates:** The preparation of financial statements in conformity with the IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period/year. Actual results may ultimately differ from those estimates.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

3. PRINCIPAL ACCOUNTING POLICIES

The principal accounting policies adopted in the preparation of the accompanying financial statements is the following:

(a) Basis of Consolidation : The Company's accompanying consolidated financial statements include the financial statements of the parent Company, as well as of all the subsidiaries that are controlled by the Parent Company. Control is presumed to exist when direct or indirect ownership retains the majority of voting interest or has the power to control the Board of Directors. Subsidiaries are consolidated from the date on which effective control is transferred to the company and cease to be consolidated from the date in which control ceases to exist.

The consolidated financial statements include the financial statements of a subsidiary (Physiotherapy Center S.A.), in which although the direct parent company holds less than 50% of the voting rights, controls it through the ability of appointing the majority of members of the Board of Directors.

All intercompany transactions and balances have been eliminated in the accompanying consolidated financial statements. Where necessary, accounting policies of the subsidiaries have been revised to ensure consistency with the policies adopted by the Group. A full list of the consolidated subsidiaries together with the related ownership interests is provided In Appendix II.

(b) Investments in Associates: The Group's investments in other entities, in which the company exercises significant influence are accounted with the equity method. Under this method, the investment in an associate is recognized at acquisition cost in addition to the changes in the percentage of the Group in the associate's equity after initial date of acquisition, less possible provisions for impairment. The consolidated statement of income reflects the Group's share in the results of the associate.

(c) Other Investments and Shares: The other investments and shares are constituted by investments in companies in which the Company does not exercise control nor has a significant influence in their activities. Their initial recognition takes place at their acquisition cost, which reflects the fair value of the amount invested including the direct expenses related to the purchase of the investment.

The investments, except of those in subsidiaries, associates and joint ventures, are classified as trading portfolio, financial instruments valued at fair value through income statement and held until maturity. Generally the investments held for trading and the financial instruments at fair value through income statement are valued at fair value and the gains or losses that arise, are recognized as a separate element of the equity for investments held for trading and of the consolidated income statement for the financial instruments at fair value through income statement. The held to maturity investments are valued at amortized cost by applying the effective interest rate method and the relevant results of the discount are recognized in the consolidated income statement through amortization or due to sale.

Based on the previous GAS (which were adopted by the Company until the 31st of December 2004), it was not required for these investments to be classified and valued at the lower price between acquisition cost and their current cost with the current cost to be defined as follows:

- For the companies, whose shares are publicly traded the average daily price of the last month of every year.
- For the companies, whose shares are not publicly traded, the proportion of the book value that relates to the Group.

(d) Investments in subsidiaries and associates (stand alone financial statements): The investments of the parent Company in the subsidiaries, which are consolidated, as well as in the associates are valued at their acquisition cost less accumulated impairment loss.

(e) Conversion of foreign currencies: The base currency of the Company and of its Greek subsidiaries is Euro. The transactions involving other currencies are converted into Euro using the exchange rates that were in effect at the time of the transactions.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

At the balance sheet date monetary assets and liabilities which are denominated in other currencies are adjusted in order to reflect the current exchange rates.

Gains and losses resulting from year end FX adjustments of monetary assets and liabilities are reflected in the accompanying income statement. Gains and losses resulting from transactions are reflected in the accompanying statement of income also. The base currency of the Group's foreign subsidiaries is the official currency of the related country in which each subsidiary operates. Thereafter, at each reporting date all balance sheet accounts of these subsidiaries are converted into Euro using the exchange rate in effect at the balance sheet date. Revenues and expenses are converted based on the weighted average rate of exchange that prevailed during the year.

- (f) **Intangible Assets:** Intangible assets are mainly consisted of software and commercial rights. These are amortized over their estimated useful lives which are set to five years.
- (g) **Research and Product Development Cost:** Research costs are expensed as incurred. Development expenditure is mainly incurred for the development of new products. Costs incurred for the development of an individual project are recognized as an intangible asset only when the requirements of IAS 38 "Intangible Assets» are met.
- (h) **Revenue recognition:** Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. The following particular recognition criteria must also be met as it is recognized.

Sale of Services

The Sale of Services revenue is accounted according to the extent of service completion.

Sale of goods

The sale of goods revenue, net of trade discounts sale, incentives and the related VAT, is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer.

Interests

The interest revenue is recognized on the accrual basis of accounting.

- (i) **Property, Plant and Equipment:** Land and buildings are valued at historical cost (deemed cost based on the provisions of IFRS 1), less accumulated depreciation and any impairment in value. Machinery, transportation equipment, as well as the furniture and the rest of the equipment are measured at historical cost less the accumulated depreciation and any impairment in value.

As more fully described in Note 11, the Company proceeded to a fair valuation of its land and buildings, machinery and other equipment as at January 1, 2004 and these fair values were used as deemed cost on the date of transition to the IFRS. The resulted revaluation surplus was credited to retained earnings.

Repairs and maintenance are charged to expenses as incurred. Major improvements are capitalized to the cost of the asset to which they relate when they extend the useful life, increase the earnings capacity or improve the efficiency of the respective assets.

An item of property and plant is derecognized upon sale or disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on derecognition of the asset, is included in the consolidated statement of income in the year the item is derecognized.

- (j) **Depreciation:** Depreciation is calculated based on the straight-line method at rates, which approximately reflect the average useful lives of relative assets.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The rates used are the following:

<u>Classification</u>	<u>Annual rate</u>
Buildings	2%
Machinery and Equipment	10%- 10,80%
Equipment of Transportation	6%-10%
Furniture and rest of Equipment	10%- 20%

(ja) Goodwill: As more fully described in Notes 2 and 9, goodwill on business combinations, which occurred prior to the date of transition to IFRS was recognized according to the provisions of IFRS 1 “First Time Adoption of IFRS”. Goodwill on acquisitions was initially measured at cost, being the excess value of the cost of the business combination over the acquirer’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities assumed of the acquiree. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill on acquisitions after March 31, 2004 is not amortized and goodwill already carried in the consolidated balance sheet is not amortized after January 1, 2004. Goodwill is reviewed for impairment, annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired.

At the acquisition date, any goodwill acquired is allocated to each of the cash generating units expected to benefit from the combination’s synergies. Impairment is determined by assessing the recoverable amount of the cash-generating units, to which the goodwill relates. When the recoverable amount of the cash-generating unit is less than the carrying amount, an impairment loss is recognized. Where goodwill forms part of a cash-generating unit and part of the operation within that unit, is disposed of, the goodwill associated with the operation disposed of, is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of, in this circumstance is measured on the basis of the relative values of the operation disposed of and the portion of the cash-generating unit retained.

(jb) Impairment of Assets: With the exception of goodwill and intangibles with indefinite life, which are reviewed for impairment at least annually, the carrying value of other non-current assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Whenever the carrying value of an asset exceeds its recoverable amount a respective impairment loss is recognized in the consolidated statement of income. The recoverable amount is measured as the higher of net selling price and value in use. Net selling price is the amount obtainable from the sale of an asset in an arm’s length transaction between knowledgeable, willing parties, after deducting any direct incremental selling costs, while value in use is the present value of estimated future cash flows expected to arise from continuing use of the asset and from the revenue due to its disposal at the end of its estimated useful life. For the purpose of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows.

(jc) Inventories: Inventories are reported at the lower value between the cost and the net realizable value. Cost of finished and semi-finished products includes all costs incurred in bringing inventories to their current location and state of manufacture and comprises raw materials, labour, an applicable amount of production overhead (based on normal operating capacity, but excluding borrowing costs) and packaging. The cost of raw materials and finished goods is determined based on the weighted average basis. Net realizable value for finished goods is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary, to make the sale. The net realizable value for raw materials is the estimated replacement cost in the ordinary course of business.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(jd) Accounts Receivable and Credit Policy: Short-term receivables are presented at their nominal value, net of provisions for potential non collectible accounts, while long-term receivables (balances that deviate from normal credit terms) are reported at the amortized cost based on the actual interest rate method. The Company has established criteria for granting credit to customers who are generally based upon the size of the customer's operation and consideration of relevant financial data. Business is generally conducted with such customers under normal terms. At each balance sheet date all due or potentially uncollectible accounts are assessed for determining whether the appropriate allowance for doubtful accounts is needed or not. The balance of such allowance for doubtful accounts is appropriately adjusted at each balance sheet date in order to reflect all possible risks. Any amount written-off with respect to customer account balances is charged against the existing allowance for doubtful accounts. It is the Group's policy not to write-off an account until all possible legal action has been exhausted.

(je) Credit Risk Concentration: The concentration of credit risk is limited in relation to the total amount of receivables due to the great dispersion of the balances.

(jf) Cash and Cash Equivalents: The Company considers time deposits and other highly liquid investments with original maturity of three months or less, to be cash equivalents. For the purpose of the cash flow statements, cash and cash equivalents consist of cash at hand and in banks and of cash and cash equivalents as defined above.

(jg) Long-term Liabilities: All long-term liabilities are initially recognized at cost. After initial recognition loans and borrowings denominated in foreign currency are reported using the spot rate at each reporting date. The interest costs are recognized on the accrual basis of accounting.

(jh) Borrowing Costs: Borrowing Costs are recognized as an expense in the period in which they are incurred.

(ji) Provision for Retirement Indemnities: Staff Retirement obligations are calculated at the discounted value of the future retirement benefits deemed to have accrued at year-end, based on the employees earning retirement benefit rights throughout the expected working period. Retirement obligations mentioned above are calculated on the basis of financial and actuarial assumptions and are determined using the Projected Unit credit actuarial valuation Method. Net pension costs for the period are included in payroll in the accompanying income statement and consist of the present value of benefits earned in the year, interest cost on the benefit obligation, past service cost, actuarial gains or losses and any additional pension charges. Past service costs are recognized on a straight-line basis over the average period until the benefits under the plan become vested. Unrecognized actuarial gains or losses are recognized over the average remaining service period of active employees and included as a component of net pension cost for a year if, as of the beginning of the year, it exceeds 10% of the future projected benefit obligation. The retirement benefit obligations are not funded.

(k) State Pension: The Company's personnel is covered by several State sponsored pension funds for private sector employees, (I.K.A., T.S.A.Y.) covering post-retirement pensions, and healthcare benefits. Each employee is required to contribute a portion of its monthly salary to the fund, with the company also contributing a portion. Upon retirement, the pension fund is responsible for paying the employees retirement benefits. At such, the company has no legal or constructive obligation to pay future benefits under this plan.

(ka) Income Taxes (Current and Deferred): Current and deferred income taxes are computed based on the stand alone financial statements of each of the entities included in the consolidated financial statements, in accordance with the tax rules in force in Greece or other tax jurisdictions in which foreign subsidiaries operate. Income tax expense is computed based on each entity's profits as adjusted in its tax returns, additional income taxes resulting from tax audits by the tax authorities and deferred income taxes, using substantively enacted tax rates.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Deferred income tax is computed, using the liability method, on all temporary differences at the balance sheet date between the tax bases and the carrying amounts of assets and liabilities. Deferred income tax liabilities are recognized for all taxable temporary differences:

- Except cases, where the deferred income tax liability arises from goodwill amortization or the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss, and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interest in joint ventures, except where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognized for all discounted temporary differences and transferred tax assets and losses, to the extent where it is possible that taxable profit will be available which will be used against the discounted temporary differences and the transferred unused taxable assets and losses.

- Except cases where the deferred tax asset regarding the discounted temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interest in joint ventures, an income deferred tax is recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and there will be available taxable profit which will be used against temporary differences

The deferred tax assets are reviewed at each balance sheet date and reduced to the extent, where it is not considered as possible that enough taxable profits will be presented against which, a part or the total deferred tax assets can be utilized.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on the tax rates (and the laws) that have been enacted or substantively enacted at the balance sheet date.

The income tax relating to items recognized directly in equity, is recognized in equity and not in the income statement.

(kb) Leases: Finance leases, which transfer to the Company substantially all the risks and benefits incidental to ownership of the leased item, are capitalized at the inception of the lease at the fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between the finance charges and the reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly to income. Capitalized leased assets are depreciated over the shorter of the estimated useful life of the asset or the lease term.

Leases where the lessor retains substantially all the risks and benefits of ownership of the asset are classified as operating leases. Operating lease payments are recognized as an expense in the income statement on the straight line basis over the lease term.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(kc) Government Grants: Government grants which primarily relate to the subsidization of property, plant and equipment are recognized where there is reasonable assurance that the grant will be received and all attaching conditions will be complied. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to the income statement over the expected useful life of the relevant asset by equal annual installments. When the grant relates to an expense item, it is recognized against these expenses over the periods necessary to match the grant on a systematic basis to the costs that it is intended to compensate.

(kd) Provisions and Contingencies: Provisions are recognized when the Company has a present legal or presumed/ imputed obligation as a result of past events, it is probable that an outflow of resources will be required to settle this obligation and a reliable estimate of the amount of the obligation can be made. Provisions are reviewed at each balance sheet date and adjusted to reflect the present value of the expenditure expected to be required to settle the obligation. If the effect of time value of money is material, provisions are determined by discounting the expected future cash flows at a pretax rate that reflects current market assessments of the time value of money and, where appropriate the risks specific to the liability. Contingent liabilities are not recognized in the consolidated financial statements but they are disclosed unless the possibility of an outflow of resources embodying economic benefits is remote. Contingent assets are not recognized in the consolidated financial statements but are disclosed when an inflow of economic benefits is probable.

(ke) Earnings per Share: Basic earnings per share (EPS) are computed by dividing net income by the weighted average number of common shares outstanding during each year, excluding the average number of common shares purchased by the group as treasury shares (ownshares).

Diluted earnings per share are calculated by dividing the net profit attributable to equity holders of the parent company (after deducting interest on convertible shares, net of tax) by the weighted average number of shares outstanding during the year, (adjusted for the effect of dilutive convertible shares).

(kf) Segment reporting : The group has one segment, the health care services. It is also involved mainly in the Greek territory and its activities abroad do not have sufficient extend in order to consist a segment. Consequently, the presentation of relevant financial information is not necessary.

(kg) Derivative Financial Instruments: The Group does not use derivative Financial Instruments .

(kh) New Standards and Interpretations: During 2005, the Interpretation 4 "Determining whether an Arrangement contains a Lease" and Interpretation 5 "Rights to Interests arising from Decommissioning Restoration and Environmental Rehabilitation Funds" were issued and will be applied from January 1, 2006 which are not expected to affect the Group's financial statements.

Also the provisions of IFRS 6 "Exploration for and Evaluation of Mineral Resources" which is applied from January 1, 2005, has not effect in the Group's financial Statements.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

4. PAYROLL COST:

The Payroll Cost that is included in the accompanying financial statements is analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>30/9/2004</u>	<u>30/9/2005</u>	<u>30/9/2004</u>
Wages and Salaries	36.362	34.293	34.958	32.981
Social security costs	9.428	8.798	9.055	8.473
Provision for retirement indemnities	987	1.091	987	1.091
Other staff expenses	1.274	1.480	1.216	1.426
Total payroll	48.051	45.661	46.216	43.971
Less: amounts charged to cost of sales	(38.390)	(36.081)	(37.251)	(35.045)
Payroll expensed (Note 6)	9.661	9.580	8.965	8.926

5. DEPRECIATION AND AMORTISATION:

Depreciation and amortization accounted in the accompanying financial statements is analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>30/9/2004</u>	<u>30/9/2005</u>	<u>30/9/2004</u>
Depreciation of property land and equipment (Note 11)	8.003	7.498	7.709	7.297
Amortization of intangible assets (Note 12)	27	100	27	100
	8.030	7.598	7.736	7.397
Less: depreciation and amortization charged to cost of sales	(6.786)	(6.546)	(6.549)	(6.402)
Depreciation and amortization expensed (Note 6)	1.244	1.052	1.187	995

6. Administrative Expenses and Distribution Costs:

The administrative expenses and distribution costs that are presented in the accompanying financial statements are analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>30/9/2004</u>	<u>30/9/2005</u>	<u>30/9/2004</u>
Payroll cost (Note 4)	9.661	9.580	8.965	8.926
Third party fees	822	764	740	753
Depreciation and amortization (Note 5)	1.244	1.052	1.187	995
Repairs and maintenance	1.317	944	1.190	838
Other	4.330	4.636	3.541	4.089
Total	17.374	16.976	15.623	15.601

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

7. OTHER INCOME / (EXPENSES):

The other income / (expenses) that are presented in the accompanying financial statements are analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>30/9/2004</u>	<u>30/9/2005</u>	<u>30/9/2004</u>
Income from rentals/other services	1.387	1.372	1.387	1.372
Government Grants	37	165	37	165
Other Income	121	112	105	93
Total	1.545	1.649	1.529	1.630

8 FINANCIAL INCOME/(COSTS):

The financial income/ (costs) that are presented in the accompanying financial statements are analyzed as follows:

The Group	30th September 2005	30th September 2004
Interest on non-current loans/borrowings	(2.351)	(2.729)
Interest on current loans/borrowings & relevant expenses	(352)	(310)
Factoring Commissions	(651)	(589)
Leasing	(585)	(403)
Total financial costs	(3.940)	(4.031)
Gains from sale of investments & shares (gain from lease back sale)	376	
Dividends from investments in companies and from shares	55	9
Interests on deposits	67	24
Total financial income	498	33
Financial income/(costs)	(3.442)	(3.998)

The Company	30th September 2005	30th September 2004
Interest on non-current loans/borrowings	(2.351)	(2.729)
Interest on current loans/borrowings & relevant expenses	(309)	(269)
Factoring Commissions	(651)	(589)
Leasing	(559)	(380)
Total financial costs	(3.870)	(3.967)
Gains from sale of investments & shares (gain from lease back sale)	376	
Dividends from investments in companies and from shares	1.369	955
Interests on deposits	46	15
Total financial income	1.791	970
Financial income/(costs)	(2.079)	(2.997)

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

9. INCOME TAXES:

According to the tax legislation, the tax rate applicable in companies for the period of 2005 is 32% (35 % until the 31st of December 2004).

In November of 2004 a new tax act was approved, according to which, the tax rate of the companies is gradually reduced from 35% to 25%. In particular, for the periods of 2005 and 2006 the tax rate will be reduced to 32% and 29% respectively, while from the period of 2007 onwards it will reach 25%.

The provision for income taxes presented in the accompanying financial statements is analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>30/9/2004</u>	<u>30/9/2005</u>	<u>30/9/2004</u>
Current income taxes:				
Current income tax charge	1.784	2.299		975
Deferred income taxes	2.209	1.193	2.165	1.136
Other taxes	10	115		
Total provision for income taxes	4.003	3.607	2.165	2.111

The Company has been audited by the tax authorities up to 31st of December 2002. Regarding its subsidiaries, the tax authorities have not audited their books and their elements for the years mentioned in Appendix II.

In a future tax audit of the related unaudited years, additional taxes and penalties may be assessed to the Company and to its subsidiaries. The Company regards that the outcome of the tax audits and the amount of the possible added taxes and fines, is not possible to estimate and, thus, no estimate has been made in the financial statements related to this subject.

It is noted that in the parent company a tax audit is in progress of the unaudited years 2003 and 2004, which until today has not been finished.

The deferred income taxes related to the temporary differences between the book values and the tax bases of assets and liabilities are calculated using the applicable statutory income tax rate.

	<u>The Group</u>	<u>The Company</u>
Beginning balance, January 1 st 2004	(15.428)	(11.922)
Charged directly to equity		
Charged to the consolidated statement of income	6.092	5.123
Ending balance, December, 31st 2004	(9.336)	(6.799)
	<u>The Group</u>	<u>The Company</u>
Beginning balance, January 1 st 2005	(9.336)	(6.799)
Charged directly to equity		
Charged to the consolidated statement of income	(2.209)	(2.165)
Ending balance, September, 30th 2005	(11.545)	(8.964)

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	The Group		The Company	
	30 th September 2005	31 st December 2004	30 th September 2005	31 st December 2004
Deferred income tax Liabilities				
- Property plant and equipment	(16.662)	(15.679)	(14.162)	(13.179)
-Leases	(1.945)	(1.701)	(1.780)	(1.521)
- Other	(228)	(228)	(228)	(228)
	(18.835)	(17.608)	(16.170)	(14.927)
Deferred income tax Assets				
- Accounts receivable	1.035	1.035	1.035	1.035
- Deferred expenses	2.366	3.788	2.280	3.645
- Taxable loss for the period 1.1-30.09.05	239		239	
- Investment measurement	1.209	1.253	1.209	1.253
- Provision for retirement indemnities	2.442	2.195	2.442	2.195
	7.291	8.272	7.205	8.128
Net deferred income tax Liabilities	(11.545)	(9.336)	(8.965)	(6.799)

The effect of the deferred taxes in debits/(credits) of the income statement is the following:

	The Group		The Company	
	30 th September 2005	30 th September 2004	30 th September 2005	30 th September 2004
Deferred income tax Liabilities				
- Property plant and equipment	(983)	352	(983)	352
- Leases	(245)	(635)	(259)	(590)
- Other				
	(1.228)	(283)	(1.242)	(238)
Deferred income tax Assets				
- Accounts receivable		223		223
- Deferred expenses	(1.422)	(1.515)	(1.364)	(1.502)
- Taxable loss for the period 1.1-30.09.05	239		239	
- Investment measurement	(44)		(44)	
- Provision for retirement indemnities	247	382	247	382
	(980)	(910)	(922)	(897)
Debit of deferred income tax	(2.208)	(1.193)	(2.164)	(1.135)

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

10. EARNINGS PER SHARE:

The calculation of basic earnings per share in the 30th of September 2005 and 2004 is the following:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>30/9/2004</u>	<u>30/9/2005</u>	<u>30/9/2004</u>
Net profit attributable to equity holders of the parent company	7.052	5.132	6.517	4.876
Weighted average number of shares in circulation/outstanding	83.985.980	83.985.980	83.985.980	83.985.980
Basic earnings per share				
Net profit attributable to equity holders of the parent company	0,08	0,06	0,08	0,06

11. PROPERTY LAND AND EQUIPMENT:

Property, land and equipment is analyzed as follows:

Movement for year 2004 – Group

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction/ in Progress	Total
<u>Cost or measurement</u>							
Balance in 01/01	59.676	159.758	51.377	4.748	24.829	7.897	308.285
Additions	41		999	86	807	6.540	8.471
Sales -Deletions	(620)	(4.324)					(4.943)
Leases	3.772	4.373	247				8.392
Ending total	62.869	159.807	52.623	4.834	25.636	14.437	320.204
Depreciation							
Balance in 01/01		(31)	(14.287)	(1.100)	(11.176)		(26.594)
Year's Additions		(3.214)	(3.005)	(165)	(2.433)		(8.818)
Sales -Deletions		568		24			592
Leases			(1.566)				(1.566)
Period Total		(2.646)	(4.571)	(142)	(2.433)		(9.792)
Ending total		(2.677)	(18.857)	(1.242)	(13.610)		(36.386)
Balance at the end of period	62.869	157.129	33.765	3.592	12.026	14.437	283.818

Movement for the Nine Month Period of 2005 – Group

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction/ in Progress	Total
<u>Cost or measurement</u>							
Balance in 01/01	62.869	159.807	52.623	4.834	25.636	14.437	320.204
New consolidated company (Medsana SRL)		1	12		3		16
Exchange Differences	5	47	69	4	8	12	144
Additions	89	965	688	12	799	1.777	4.330
Sales -Deletions			(81)	(2.428)			(2.509)
Transfers						(110)	(110)
Leases			452				452
Ending total	62.963	160.819	53.763	2.422	26.446	16.116	322.529
Depreciation							
Balance in 01/01		(2.677)	(18.857)	(1.242)	(13.610)		(36.386)
New consolidated company (Medsana SRL)			(9)		(2)		(11)
Exchange Differences		(2)	(16)	(1)	(1)		(20)

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Year's Additions		(2.352)	(2.153)	(144)	(2.016)		(6.665)
Sales -Deletions			24				24
Leases		(66)	(1.271)				(1.337)
Period total		(2.420)	(3.425)	(145)	(2.020)		(8.010)
Ending total		(5.097)	(22.282)	(1.387)	(15.630)		(44.396)
Balance at the end of period	62.963	155.722	31.481	1.035	10.816	16.116	278.13

Movement for year 2004 – Company

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction/ in Progress	To
Cost or measurement							
Balance in 01/01	43.148	158.204	47.080	2.231	24.391	5.993	281.847
Additions			840	4	747	5.536	7.127
Sales -Deletions	(620)	(4.419)					(5.039)
Leases	3.772	4.373	247				8.392
Ending total	46.300	158.158	48.167	2.235	25.138	11.529	291.529
Depreciation							
Balance in 01/01			(12.873)	(1.059)	(10.881)		(24.813)
Year's Additions		(3.203)	(2.836)	(158)	(2.409)		(8.606)
Sales -Deletions		563					563
Leases			(1.498)				(1.498)
Period Total		(2.640)	(4.334)	(158)	(2.409)		(9.541)
Ending total		(2.640)	(17.207)	(1.216)	(13.291)		(34.354)
Balance at the end of period	46.300	155.517	30.960	1.019	11.848	11.529	257.175

Movement for the Nine Month Period of 2005 – Company

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction/ in Progress	T
Cost or measurement							
Balance in 01/01	46.300	158.158	48.167	2.235	25.138	11.529	291.529
Additions	89	713	308	12	671	1.696	3.489
Sales -Deletions							
Leases							
Ending Balance	46.389	158.871	48.475	2.247	25.809	13.225	297.726
Depreciation							
Balance in 01/01		(2.640)	(17.207)	(1.216)	(13.291)		(34.354)
Additions		(2.336)	(2.062)	(119)	(2.002)		(6.515)
Sales -Deletions							
Leases		(66)	(1.125)				(1.191)
Period Total		(2.402)	(3.187)	(119)	(2.002)		(7.708)
Ending total		(5.042)	(20.394)	(1.335)	(15.293)		(42.064)
Balance at the end of period	46.389	153.829	28.081	912	10.516	13.225	255.662

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Use of fair value as deemed cost: Within year 2004 the Group appointed an independent firm of appraisers to conduct a valuation of its land buildings and machinery as of January 1, 2004 (transition date to IFRS). The valuations were performed based on appropriate valuation techniques depending on the nature and the usage of the valued fixed assets.

The main valuation techniques used were as follows:

- The market approach for land,
- The market approach and/or income approach for the urban buildings and,
- The depreciated replacement cost method for the industrial buildings and the machinery and equipment.

In addition, the appraisers determined the economic useful lives of the items of tangible assets from the date of acquisition or construction, which are set forth in Note 3. Depreciation in the accompanying income statements has been determined after deducting from the economic useful life of each fixed asset the years elapsed from the date of acquisition or construction through to the IFRS transition date.

The Company used the fair values determined as above in its opening IFRS balance sheet as deemed cost based on the exception provided in IFRS 1.

The aggregate adjustments to the respective carrying amounts reported under previous GAS, by category of fixed assets, are as follows:

	<u>The Group</u>			<u>The Company</u>		
	<u>1st January 2004</u>			<u>1st January 2004</u>		
	<u>Increase</u>	<u>Decrease</u>	<u>Total</u>	<u>Increase</u>	<u>Decrease</u>	<u>Total</u>
	<u>in Value</u>	<u>in Value</u>		<u>in Value</u>	<u>in Value</u>	
Land	38.717	-	38.717	28.715	-	28.715
Buildings	30.761	-	30.761	30.761	-	30.761
	<u>69.477</u>	<u>-</u>	<u>69.477</u>	<u>59.476</u>	<u>-</u>	<u>59.476</u>

Tax revaluation of land and buildings: In accordance with Greek tax legislation, land and the buildings are revaluated every four years based on non industry specific indexes that were announced through respective Ministerial Decisions. The latest of this revaluation, which was applied in December 31, 2004, was reversed for IFRS reporting purposes on the basis of not meeting the criteria set forth in IAS 16, however, it resulted to an increase of the tax base of the related assets. The net surplus on land and buildings was taxed at 2% and 8% respectively.

There are no restrictions on title or transfer or other encumbrances on the Group's land and buildings. In addition, no item of land, building and machinery equipment has been pledged as security for liabilities.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

12. INTANGIBLE ASSETS

The Group

	Goodwill	Rights Licenses	Other	Total
Cost				
in 1 st January 2004		398	671	1.069
Additions			34	34
Sales - Deletions			(135)	(135)
In 31 st December 2004		398	570	968
Accumulated amortization				
In 1 st January 2004			(558)	(558)
Additions			(136)	(136)
Sales – Deletions			135	135
in 31 st December 2004			(559)	(559)
Balance 31 December 2004		398	11	409
	Goodwill	Rights Licenses	Other	Total
Cost				
in 1 st January 2005		398	570	968
Additions	1.979		22	2.001
Transfers - Deletions			8	8
In 30 th September 2005	1.979	398	600	2.977
Accumulated amortization				
In 1 st January 2005			(559)	(559)
Additions			(27)	(27)
Transfers/ Deletions			(8)	(8)
Foreign exchange differences				
In 30 th September 2005			(594)	(594)
Balance 30 September 2005	1.979	398	6	2.383

The goodwill amounted to €1.979 resulted from the acquisition of a further 5% of the subsidiary's share capital IATRIKI TECHNIKI S.A., a company that is operating in Greece in the sector of medical and surgical instrument production and trading, as well as of all kinds of sanitary/health equipment. The Group acquires the 56% of the share capital, while the buying-out of the further 5% that was typically completed in the last quarter of 2005, has been recognized according to the buy-out method and represents the difference between the paid up price and the fair value of the assets that were purchased as they were valued at the respective transaction dates. Due to the fact that these transactions are recent, no impairment test on goodwill was exercised, but it will take place at the end of the year. From the progress of activities until now, no indications have arisen showing that the possibility of an impairment test must be examined.

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The Company

	<u>Rights Licenses</u>	<u>Other</u>	<u>Total</u>
Cost			
in 1 st January 2004	398	671	1.069
Additions		34	34
Sales - Deletions		(135)	(135)
In 31 st December 2004	<u>398</u>	<u>570</u>	<u>968</u>
Accumulated amortization			
In 1 st January 2004		(558)	(558)
Additions		(136)	(136)
Sales - Deletions		135	135
in 31 st December 2004		<u>(559)</u>	<u>(559)</u>
Balance 31 December 2004	<u>398</u>	<u>11</u>	<u>409</u>

	<u>Rights Licenses</u>	<u>Other</u>	<u>Total</u>
Cost			
in 1 st January 2005	398	570	968
Additions		22	22
Transfers / Deletions		8	8
In 30 th September 2005	<u>398</u>	<u>600</u>	<u>998</u>
Accumulated amortization			
In 1 st January 2005		(559)	(559)
Additions		(27)	(27)
Transfers/ Deletions		(8)	(8)
Foreign exchange differences			
In 30 th September 2005		<u>(594)</u>	<u>(594)</u>
Balance 30 September 2005	<u>398</u>	<u>6</u>	<u>404</u>

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

13. INVESTMENTS IN SUBSIDIARIES

The investments of the Company in subsidiaries at the 30th September 2005 are analyzed as follows:

	Participation	Acquisition cost
Iatriki Techniki S.A.	56,00%	4.139
Phisiotherapy center S.A	33,00%	19
Axoniki Erevna S.A	50,50%	545
Erevna S.A	51,00%	503
Hospital Affiliates International	68,89%	91
Eurosite S.A	100,00%	8.335
Ortelia Holdings	99,99%	1.039
Medsana Buch	100,00%	33
Medsana Srl	78,90%	517
Athens Paediatrics Center	58,30%	169
Prostate Institute	98,90%	668
Electronystagmografiki S.A.	100,00%	18
		16.076
Impairment loss		(2.491)
Balance		13.585

The above-mentioned subsidiaries are consolidated, except from Athens Pediatrics Center SA , the Prostate Institute and Electronystagmografiki S.A., which are under liquidation procedure and their acquisition cost is totally deleted in the Company's retained earnings. The operation of these companies was interrupted before the transition date, the assets and liabilities of their balance sheets are of minor significance and the liquidation procedure does not entail significant costs for the Company. Until the reporting date of the accompanying financial statements no final judicial decision has been issued for their dissolution and their final deletion from the S.A. register.

The acquisition cost in Ortelia Holdings SA and in Medsana Srl has been completely deleted in the stand alone financial statements of the Company, according to the provisions of IAS 27 and 38. These companies, do not present any operation and their accounting value is greater of their recoverable amount. At the transition date in IFRS, an impairment test took place in the above mentioned investments, during which, it was attributed in Company's cash generating units. The recoverable amount, which in this case was the value of use, was lower than the carrying amount and the impairment loss arose and amounted to € 2.491, was charged against the retained earnings of 1st of January 2004.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

14. INVESTMENTS IN ASSOCIATES CONSOLIDATED BY THE EQUITY METHOD

These concern Company's investments in the capital share of the following companies in a percentage between 20% and 50% and in which no important influence is exercised.

	<u>Percentage</u>	<u>Acquisition cost</u>
Nevrolitourgiki	25,10%	6
Medisoft	45,00%	132
In Health	30,37%	340
Aggiologiki Dierevnisi	20,00%	2
Herodikos Ltd	20,00%	19
		<u>499</u>
Impairment loss		(499)
Balance		0

The carrying amount of the above companies is deleted in the Company's Equity at a time prior the transition date and the same classification is preserved since the 1st January.

15. INVENTORIES:

The inventories are analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30.9.2005</u>	<u>31.12.2004</u>	<u>30.9.2005</u>	<u>31.12.2004</u>
Merchandise	102	170		
Direct, indirect, raw material and consumable material	4.742	5.172	4.701	5.126
Finished and semi-finished products	45	45		
TOTAL	4.889	5.387	4.701	5.126

16. TRADE ACCOUNTS RECEIVABLE:

The trade accounts receivable are analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30.9.2005</u>	<u>31.12.2004</u>	<u>30.9.2005</u>	<u>31.12.2004</u>
Customers	74.783	64.223	73.706	63.321
Short-term receivables from subsidiaries				70
Checks receivable (postdated) & bills receivable	10.068	9.061	9.728	8.983
Payments on account for imports	105		15	
Doubtful debtors	309	244	300	244
Less: Provision for impairment	(3.200)	(3.200)	(3.200)	(3.200)
TOTAL	82.065	70.328	80.549	69.418

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

17. PREPAYMENTS AND OTHER RECEIVABLES:

	<u>The Group</u>		<u>The Company</u>	
	<u>30.9.2005</u>	<u>31.12.2004</u>	<u>30.9.2005</u>	<u>31.12.2004</u>
Advances	843	685	796	614
Other accounts receivable	8.680	8.235	6.870	6.745
Short-term receivables from subsidiaries		33	4.123	5.490
Prepaid expenses and other transit debit balances	4.199	1.165	4.133	1.090
TOTAL	13.722	10.118	15.922	13.939

18. CASH AND CASH EQUIVALENTS:

The cash and cash equivalents are analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>31/12/2004</u>	<u>30/9/2005</u>	<u>31/12/2004</u>
Cash in hand	396	418	312	391
Deposits (sight and time)	4.712	6.608	3.827	6.014
Total	5.108	7.026	4.139	6.405

The bank deposits are lent at interest with floating interest rates based on the monthly interest rates of bank deposits. The income from sight and time bank deposits interest is recognized in accrual basis of accounting.

19. SHARE CAPITAL:

The share capital of the Company consists of 83.985.980 common nominal shares, with nominal value €0,31 each. The share capital of the Company was not differentiated during the period from 1, January 2004 until the approval date of the interim financial statements. The Company's shares are publicly traded on the Athens Stock Exchange (main market).

According to the Shareholders Record of the Company, in the 30th of September 2005, the shareholders with a holding a percentage in the Company greater than 2 % were the following:

	<u>Number of shares acquired</u>	<u>Sharing percentage 30th September 2005</u>
G. Apostolopoulos Holdings S. A.	47.633.843	56,716%
Georgios Apostolopoulos	1.900.591	2,263%
Credito Italiano Milano	3.096.370	3,687%
Banca Commerciale Italiana Milan	3.464.843	4,126%
Morgan Stanley and Co International Ltd	3.006.060	3,579%
Other shareholders with sharing percentage < 2%	24.884.273	29,629%
TOTAL	83.985.980	100,000%

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The share premium of the Company resulted from the period of 1991 until the period of 2002, with a total amount of €15.267, by the issuing of shares against cash, in value greater than their nominal value.

20. LEGAL, TAX FREE AND SPECIAL RESERVES:

The legal, tax free and special reserves are analyzed as follows:

The Group

	30th September 2005	31st December 2004
Legal reserve	5.998	5.998
Less: Impairment of investments	(3.039)	(3.039)
Tax free and specially taxed reserves	70.548	70.548
Other	588	521
TOTAL	74.095	74.028

The Company

	30th September 2005	31st December 2004
Legal reserve	5.818	5.818
Less: Impairment of investments	(3.039)	(3.039)
Tax free and specially taxed reserves	70.548	70.548
Other	440	440
TOTAL	73.767	73.767

Legal Reserve: According to the Greek Company law, the companies are obliged to form at least 5% of their annual net profits, as they are represented in the accounting books, in legal reserve, until the accumulated amount of the legal reserve reaches at least the 1/3 of the capital share. The above-mentioned reserve cannot be distributed during the operation of the Company.

Tax free and Specially Taxed Reserves: The untaxed and specially taxed reserves represent interest income, which are tax free or taxed by 15% at their source. The particular income is not taxable under the condition that adequate profits exist, from which respective untaxed reserves can be formed. According to the Greek tax legislation, this reserve is excluded from income tax, under the condition that it will not be distributed to the shareholders. The Company does not intend to distribute the particular reserve and thus it has not proceeded to the estimation of deferred income tax that would have been necessary in the case of reserve distribution.

Special Reserves: The special reserves have been formed based on the decisions of the shareholders' General Assemblies. The Company does not intend to distribute the particular reserves.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

21. LOANS:

	The Group		The Company	
	<u>30.9.2005</u>	<u>31.12.2004</u>	<u>30.9.2005</u>	<u>31.12.2004</u>
Non-current loans				
Syndicated bank loan	57.214	68.467	57.056	68.467
Leases	9.467	12.038	9.070	12.038
	66.681	80.505	66.126	80.505
Current loans				
Bank loans	12.311	7.445	12.000	7.000
Non-current loans payable in the next 12 months	22.996	22.823	22.823	22.823
Leases	4.336	4.551	4.062	4.296
Other (factoring)	13.262	7.105	13.262	7.105
	52.905	41.924	52.146	41.224
Total of loans	119.586	122.429	118.273	121.729
	The Group		The Company	
	<u>30.9.2005</u>	<u>31.12.2004</u>	<u>30.9.2005</u>	<u>31.12.2004</u>
Maturity of non-current loans				
Between 1 & 2 years	22.996	22.823	22.823	22.823
Between 2 & 5 years	34.218	45.644	34.233	45.644
Over 5 years	0	0	0	0
	57.214	68.467	57.056	68.467

The Group's borrowing mainly concerns the Syndicated Loan, with initial amount of €102.700.00,00, according to the Syndicated Loan contract from the 21/12/2001, with the Bank "ALPHA BANK" as a manager and lender Banks the following: GENERAL, NATIONAL, COMMERCIAL, EFG EUROBANK ERGASIAS, HVB FINANCE LONDON LTD, and SG FINANCIAL SERVICES. According to the contract, the purpose of this loan was the refunding of existing borrowing by the amount of €88.000.000 (85,69%) and investments in fixed assets by of the amount of €14.699.999,99 (14,31%). The loan's duration is seven years. The loan's payment in full, in 9 six-month installments has started in 28/12/2004 and will be completed in 28/12/2008. The interests concerning the above-mentioned loan are estimated according to the Euribor interest rate plus a margin of 1,40%.

The current bank loans are received by the Company and its subsidiaries for serving their needs in working capital. The relevant interest rates vary from 3,51% to 4,5%.

The loan cost has charged the year's results according to accrual basis principle.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The liabilities that result from leases concern the leasing of buildings, that arose from the sale and lease back of Company's land building and mechanical – hospital equipment. The liabilities to the lessor are analyzed as follows:

Leasing Liabilities - Minimum payments of leases:

	The Group		The Company	
	30.9.2005	31.12.2004	30.9.2005	31.12.2004
Until one year	4.930	5.302	4.636	5.040
From 2 to 5 years	5.931	8.320	5.523	8.320
After 5 years	6.093	6.661	6.093	6.661
Total	16.954	20.283	16.252	20.021
Future debits of financial cost in leasing	(3.151)	(3.693)	(3.121)	(3.686)
Present value of liabilities in Leasing	13.803	16.590	13.131	16.335

The present value of the leasing liabilities is the following:

	The Group		The Company	
	30.9.2005	31.12.2004	30.9.2005	31.12.2004
Until one year	4.322	4.551	4.062	4.296
From 2 to 5 years	4.177	6.388	3.765	6.388
After 5 years	5.304	5.651	5.304	5.651
TOTAL	13.803	16.590	13.131	16.335

Over the leased assets ownership retention exists, which will stay in force until the ending of the leasing period and the payment in full of the leases.

There are no other guaranties and commitments of ownership or use over the fixed assets and the other assets of the Group.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

22 GOVERNMENT GRANTS:

The movement in the government grants during the interim period ended in 30th September 2005 and the year ended in 31st December 2004 was the following:

	<u>The Group</u>	<u>The Company</u>
Balance in 1 st January 2004	109	109
Additions		
Depreciation	(36)	(36)
Balance in 31st December 2004	<u>73</u>	<u>73</u>
	<u>The Group</u>	<u>The Company</u>
Balance in 1 st January 2005	73	73
Additions	-	-
Depreciation	-	-
Balance in 30th September 2005	<u>73</u>	<u>73</u>

23. PROVISION FOR RETIREMENT INDEMNITIES:

(a) **Government Insurance Programs:** The contributions of the Company and the Group to the insuring funds for the period ended in 30th September 2005, were recognized as expenses and amounted to €9.055 and €9.428 respectively.

(b) **Provision for retirement indemnities:** According to the Greek employment legislation, the employees entitled to receive compensation in case of dismissal or retirement, the amount of which varies depending on the salary, the years of service and the type of retirement (dismissal or pensioning) of the employee. Employees that resign or get dismissed with a justification are not entitled to receive compensation. The payable compensation in case of retirement equals the 40% of the compensation that would have been payable in case of an unjustified dismissal. In Greece, according to the local practice, these programs are not granted. The Company debits to the results for the accrued benefits in every period with a relevant rise of the pensioning liability. The payments of the benefits performed to the pensioners every period are charged against this liability.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The movement of the net liability in the accompanying balance sheets of the Company and the Group is the following:

	<u>30th September 2005</u>	<u>31st December 2004</u>
Net liability at the beginning of period	8.781	7.326
Actual benefits paid by the Company	(70)	(150)
Expense recognized in the income statement (Note 4)	<u>1.057</u>	<u>1.604</u>
Net liability at the end of the period	9.768	8.781

An international firm of independent analogists/actuaries evaluated the Company's liabilities arising from the obligation to pay retirement indemnities.

The details and principal assumptions of the actuarial study as at 30th of September 2005 and 31st of December 2004 is the following:

	<u>The Group</u>		<u>The Company</u>	
	<u>30th September 2005</u>	<u>31st December 2004</u>	<u>30th September 2005</u>	<u>31st December 2004</u>
Present Value of un funded obligations		9.173		9.173
Unrecognized actuarial net loss		<u>(392)</u>		<u>(392)</u>
Net liability in balance Sheet		8.781		8.781
Components of net periodic pension cost:				
Service cost	784	860	784	860
Interest cost	271	316	271	316
Analogical losses	2	<u>373</u>	2	<u>373</u>
Regular charge to operations/results	1.057	1.549	1.057	1.549
Additional cost of extra benefits		<u>55</u>		<u>55</u>
Total charge to operations/results	1.057	1.604	1.057	1.604
Reconciliation of benefit obligation:				
Net liability at start of period	8.781	7.326	8.781	7.326
Service cost	784	860	784	860
Interest cost	271	317	271	317
Benefits paid	(70)	(150)	(70)	(150)
Additional cost of extra benefits		55		55
Analogical losses	2	<u>373</u>	2	<u>373</u>
Present value of obligation at the end of the period	9.768	8.781	9.768	8.781



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Principal assumptions:

Discount rate	5.0%
Rate of compensation increase	4.5%
Increase in consumer price index	2.5%

The additional cost of extra benefits relates to benefits paid to employees, who became redundant. Most of these benefits were not expected within the terms of this plan and accordingly, the excess of benefit payments over existing reserves have been treated as an additional pension charge.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

24. TRADE ACCOUNTS PAYABLE:

The trade accounts payable are analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>31/12/2004</u>	<u>30/9/2005</u>	<u>31/12/2004</u>
Suppliers	60.620	47.141	68.112	53.320
Checks outstanding (postdated)	8.553	8.795	7.747	8.627
Total	69.173	55.936	75.859	61.947

25. ACCRUED AND OTHER CURRENT LIABILITIES:

The amount represented in the accompanying consolidated balance sheet is analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2005</u>	<u>31/12/2004</u>	<u>30/9/2005</u>	<u>31/12/2004</u>
Downpayments from customers	73	145	72	90
Sundry creditors	4.351	9.705	4.069	8.994
Insurance and pension contributions payable	2.112	3.175	2.042	3.077
Non currently due current expenses	1.053	238	764	232
Other	174	372	147	153
Total	7.762	13.635	7.095	12.546

26. RELATED PARTY DISCLOSURES:

The Company and its subsidiaries are related to the following legal and natural persons:

- due to the majority of shares acquisition in its capital with Mr. Georgios Apostolopoulos and the legal persons or other business activities he is related with
- with its subsidiaries including their main shareholders and the members of their Boards of Directors
- with the members of the Company's Board of Directors.

The transactions with its subsidiaries are mainly concerning the provision of commercial services, as well as the purchasing and selling of goods. The transactions are realized within the normal operating framework of the Company.

The relative balances receivable from associates are not covered by securities, mortgages and their payment in full is conducted by cash payment within the time limits agreed between the companies in question. The Management of the Company does not regard that a provision/allowance for a possible non-collection of its subsidiary related receivables is needed; hence no provision/allowance for doubtful debtors against these receivables is formed.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The balances receivable/(payable) of the related party accounts of the Group are as follows:

<i>Receivables/(liabilities) from/to:</i>	The Group	The Group	The Company	The Company
	30 th September 2005	30 th September 2005	30 th September 2005	30 th September 2005
	<i>Receivables</i>	<i>(Liabilities)</i>	<i>Receivables</i>	<i>(Liabilities)</i>
LA VIE Assurance	2.473		2.473	
SYCHRONI ECHODIAGNOSI		(73)		(27)
IKODOMIKI EKMETALEFTIKI S.A.	2		2	
PROSTATE INSTITUTE		(34)		(34)
KORINTHIAKOS RYTHMOS		(176)		(110)
HERODIKOS Ltd	41		41	
QUS	8		8	
TRADOR A.E.	13		13	
AGGEIOLOGIKI DIEREVNISI S.A.	6		6	
ATHENS PAEDIATRICS CENTER	13		13	
ELECTRONYSTAGMOGRAFIKI S.A.		(2)		(2)
NEVROLITOURGIKI S.A.		(1)		(1)
MEDISOFT	190		190	
Total	2.746	(286)	2.746	(174)

The transactions with the related parties for the period ended in 30th September 2005 are analyzed as follows:

<i>Services</i>	The Group		The Company	
	Purchases from related parties	Sales to related parties	Purchases from related parties	Sales to related parties
LA VIE Assurance		1.016		1.016

Other Company's transactions	The Group	The Company
	Payable rents	Payable rents
KORINTHIAKOS RYTHMOS	282	209


INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

27. CONTIGENCIES AND COMMITMENTS:
(a) Lawsuits/Litigation and claims:

The Company is involved (in its capacity as defendant and as plaintiff) in various lawsuits and legal amperages in the framework of its normal operation. The Management, as well as its legal advisors estimates that all the pending cases are expected to be settled without any significant negative repercussions on the consolidated financial position of the Company or in the results of its operation.

(b) Commitments:
(i) Commitments from operational leases:

The 30th of September 2005 the Group and the Company had various agreements of operational lease, concerning the renting of buildings and transportation equipment and they end in several dates.

The renting expenses are included in the accompanying consolidated income statement of the period ended in the 30th of September 2005 and they amount to €1.056.

The minimum future payable rental leases based on non-reversible contracts of operational leases in 30th of September 2005 are as follows:

	<u>The Group</u>	<u>The Company</u>
Within one year	537	806
2-5 years	4.250	4.067
After 5 years	2.901	2.901
	<u>7.688</u>	<u>7.774</u>

(ii) Guarantees:

The Group in 30th of September 2005 had the following contingent liabilities:

- Had issued letters of guarantee for good performance for a total amount of €335 thousand.

(iii) Capital Commitments:

According to the decision of the Regular General Assembly of the Shareholders in 30/6/2005, the acquisition of the remaining 49% of the shares of "Iatriki Techniki" S.A. for the amount of €23,7 million was approved. Until the 30/9/2005 a further percentage of 5% of the Share Capital of the company was acquired for the amount of €2,4 million. Consequently for the realization of the above mentioned decision of the General Assembly the amount of €21,3 million remains to be paid up.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

28. SUBSEQUENT EVENTS:

No subsequent events after the 30th of September 2005 took place, that would have influenced the financial position and the results of the Company and the Group in the 30th of September 2005.

Marousi, 26/11/2005

THE PRESIDENT OF THE BOD

*GEORGIOS B.
APOSTOLOPOULOS*

ID NUMBER Σ 100951

*THE CHIEF EXECUTIVE
OFFICER*

*VASSILIOS G.
APOSTOLOPOULOS*

ID NUMBER. Ξ 350622

*THE CHIEF FINANCIAL
OFFICER*

PETROS ADAMOPOULOS

ID NUMBER M 253394

THE CHIEF ACCOUNTANT

PANAGIOTIS KATSICHTIS

*ID NUMBER. AB 052569
O.E.E. Rank No.17856
Classification A'*

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

ATHENS MEDICAL S.A.

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS
BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

Balance sheet as at January 1 st 2004	Balance sheet of the parent company as at January 1 st 2004		
	GAS	Difference	IFRS
ASSETS			
FORMATION EXPENSES			
Other formation expenses	16.575	(16.461)	113
FIXED ASSETS			
Intangible assets	398		398
Property, plant and equipment	183.241	72.994	256.235
Total tangible and intangible assets	183.638	72.994	256.633
Investments in subsidiaries	12.008	(841)	11.167
Investments in associates consolidated by the equity method			
Other long-term claims/Guarantees	276		276
Deferred tax assets		9.148	9.148
Total fixed assets	12.285	8.307	20.592
CURRENT ASSETS			
Inventories	4.291		4.291
Trade accounts receivable, prepayments and other receivables	59.155	16.309	75.464
Financial assets at fair value through the income statement	223		223
Cash and cash equivalents	6.184		6.184
Total current assets	69.852	16.309	86.161
Prepayments and accrued income	698	(698)	-
TOTAL ASSETS	283.048	80.451	363.498
LIABILITIES			
EQUITY			
Share capital	26.036		26.036
Share Premium	15.267		15.267
Revaluation differences – Government Grants	109	(109)	-
Reserves	68.887	198	69.085

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Retained earnings	-	21.996	21.996
Total Equity	110.298	22.085	132.383
Long-term liabilities			
Provisions		7.326	7.326
Government Grants		109	109
Long-term Loans	91.289	8.168	99.456
Deferred tax liabilities		21.070	21.070
Other long-term liabilities	1.851		1.851
Total long-term liabilities	93.140	36.672	129.812
Short-term liabilities			
Trade accounts payable, accrued and other liabilities	60.073		60.073
Short-term loans	14.661	21.694	36.355
Other short-term liabilities	4.875		4.875
Total short-term liabilities	79.610	21.694	101.303
ACCRUALS AND DEFERRED LIABILITIES			-
TOTAL LIABILITIES	283.048	80.451	363.498

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

	Balance sheet of the parent company as at December 31 st 2004		
	<u>GAS</u>	<u>Difference</u>	<u>IFRS</u>
<u>ASSETS</u>			
FORMATION EXPENSES			
Other formation expenses	12.569	(12.159)	409
FIXED ASSETS			
Intangible assets			
Property, plant and equipment	179.744	77.430	257.174
Total tangible and intangible assets	179.744	77.430	257.174
Long-term claims			
Investments in subsidiaries	11.494	(327)	11.167
Investments in associates consolidated by the equity method			
Other long-term claims/Guarantees	295	-	295
Deferred tax assets	-	8.128	8.128
Total long-term claims	11.790	7.801	19.591
Total fixed assets	204.102	73.072	277.174
CURRENT ASSETS			
Inventories	5.126	-	5.126
Trade accounts receivable, prepayments and other receivables	79.452	3.905	83.358
Cash and cash equivalents	6.406	-	6.406
Total current assets	90.984	3.905	94.889
		-	-
TOTAL ASSETS	295.086	76.977	372.063
<u>LIABILITIES</u>			
EQUITY			
Share capital	26.036	-	26.036
Share Premium	15.267	-	15.267
Revaluation differences – Government Grants	73	(73)	
Reserves	74.072	(304)	73.767

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Retained earnings	11	27.640	27.651
Total Equity	115.459	27.262	142.721
Long-term liabilities			
Provisions	-	8.781	8.781
Government Grants	-	73	73
Long-term Loans	68.467	12.038	80.505
Deferred tax liabilities		14.927	14.927
Other long-term liabilities		5.013	5.013
Total long-term liabilities	68.467	40.833	109.300
Short-term liabilities			
Trade accounts payable, accrued and other liabilities	77.012	(2.520)	74.493
Short-term loans	29.822	11.402	41.224
Other short-term liabilities	4.326	-	4.326
Total short-term liabilities	111.161	8.882	120.043
TOTAL LIABILITIES	295.086	76.977	372.063

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

ATHENS MEDICAL S.A.

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS
BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

	Income Statement of parent company at December 31 st 2004		
	<u>GAS</u>	<u>Difference</u>	<u>IFRS</u>
Turnover	182.014	-	182.014
Less: cost of sales	151.671	(715)	150.956
Gross profit	30.343	715	31.059
Plus: Other operating income	7.573	(5.013)	2.560
Total	37.917	(4.298)	33.619
Less:			
Administrative and distribution expenses	23.766	389	24.155
Operating results before financial transactions	14.150	(4.687)	9.464
Financial income/expenses	(5.166)	2.688	(2.478)
Plus or less: extraordinary results	-	-	-
Depreciation not charged to the operating cost			
PROFIT BEFORE TAXES	8.984	(1.998)	6.986
Income taxes	(1.771)	5.123	3.351
PROFIT FOR THE PERIOD	7.213	3.125	10.338

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

ATHENS MEDICAL S.A.

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

(All amounts are presented in thousands of Euro)

	Income Statement of parent company – at September 30th 2004		
	GAS	Difference	IFRS
Turnover	133.462	-	133.462
Less: cost of sales	(110.183)	(675)	(109.508)
Gross profit	23.279	(675)	23.954
Plus: Other operating income	1.630	-	1.630
Total	24.910	(675)	25.584
Less:			
Administrative and distribution expenses	(16.817)	(1.216)	(15.601)
Operating results before financial transactions	8.092	(1.891)	9.983
Financial incomes/expenses	(4.350)	(1.354)	(2.996)
Plus or less: extraordinary results			
Depreciation not charged to the operating cost			
PROFIT BEFORE TAXES	3.742	(3.244)	6.987
Income taxes	-	2.111	(2.111)
PROFIT FOR THE PERIOD	3.742	1.134	4.876

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

	Consolidated Balance Sheet at January 1 st 2004		
	Greek Accounting Standards	Difference	IFRS
ASSETS			
Long-term assets:			
Tangible fixed assets	198.794	82.896	281.690
Goodwill		0	
Intangible fixed assets	18.142	(17.631)	511
Investments in associates consolidated using the equity method.		0	
Other investments		0	
Other long-term claims	3.299	(3.003)	296
Deferred tax assets		9.296	9.296
Total long-term assets	220.235	71.557	291.792
Current Assets:			
Inventories	5.186	(29)	5.157
Trade accounts receivable,	41.049	31.364	72.413
Prepayments and other receivables	14.792	(14.792)	
Other investments	223	(0)	223
Cash and cash equivalents	6.364	350	6.714
Total current assets	67.614	16.893	84.507
TOTAL ASSETS	287.849	88.450	376.299
EQUITY AND LIABILITIES			
Equity relative to parent company shareholders			
Share capital	26.036	(0)	26.036
Share Premium	15.267	0	15.267
Treasury stock (own shares)		0	
Retained earnings		28.090	28.090
Legal, tax free and special reserves	73.131	(3.944)	69.186
Other reserves	4.073	(4.073)	
Consolidation differences	354	(354)	0
	118.861	19.718	138.579
Minority interest	4.940	(589)	4.351
Total equity	123.801	19.129	142.930

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Long-term liabilities:

Long-term loans	94.963	5.066	100.029
Other long-term liabilities	60	1.792	1.852
Provision for retirement indemnities		7.326	7.326
Government Grants		109	109
Deferred tax liabilities		24.723	24.723
Total long-term liabilities	95.023	39.016	134.039

Short-term liabilities:

Trade accounts payable	40.149	15.712	55.861
Short-term loans	15.385	22.014	37.399
Long-term liabilities payable in the next period		0	
Accrued and other current liabilities	6.725	(6.725)	
Income taxes	6.069	0	6.069
Dividends	697	(697)	0
Total short-term liabilities	69.025	30.305	99.330

TOTAL LIABILITIES AND EQUITY

	287.849	88.450	376.299
--	----------------	---------------	----------------

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

Consolidated Balance Sheet at December 31st 2004

	Greek Accounting Standards	Difference	IFRS
ASSETS			
Long-term assets:			
Tangible fixed assets	196.757	87.061	283.818
Goodwill		0	
Intangible fixed assets	14.092	(13.683)	409
Investments in associates consolidated with the equity method		0	0
Other investments		0	
Other long-term claims	1.071	(771)	300
Deferred tax assets		8.272	8.272
Total long-term assets	211.920	80.879	292.799
Current Assets:			
Inventories	5.350	37	5.387
Trade accounts receivable,	56.985	7.926	64.911
Prepayments and other receivables	19.084	(3.550)	15.534
Claims from associated companies		0	
Other investments	1	(0)	1
Cash and cash equivalents	7.035	(9)	7.026
Total current assets	88.455	4.405	92.860
TOTAL ASSETS	300.375	85.284	385.659
EQUITY AND LIABILITIES			
Equity relative to parent company shareholders			
Share capital	26.036	0	26.036
Share Premium	15.267	0	15.267
Treasury stock (own shares)		0	
Retained earnings	11.791	23.241	35.032
Legal, tax free and special reserves	70.596	3.432	74.028
Other reserves		0	
Consolidation differences	354	(354)	
	124.044	26.319	150.363
Minority interest	6.134	(1.056)	5.078

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Total equity	130.178	25.263	155.440
Long-term liabilities:			
Long-term loans	68.711	11.794	80.505
Deferred income		5.072	5.072
Provision for retirement indemnities		8.781	8.781
Government Grants	74	(0)	74
Deferred tax liabilities		17.608	17.608
Total long-term liabilities	68.785	43.255	112.040
Short-term liabilities:			
Trade accounts payable	46.726	9.211	55.937
Short-term loans	30.123	11.801	41.924
Long-term liabilities payable in the next period		0	
Accrued and other current liabilities	17.879	(4.244)	13.635
Income taxes	6.684	(0)	6.684
Dividends		0	0
Total short-term liabilities	101.412	16.767	118.179
TOTAL LIABILITIES AND EQUITY	300.375	85.285	385.659

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS BETWEEN
GREEK ACCOUNTING STANDARDS AND IFRS

	Consolidated Income Statement– at December 31st 2004		
	Greek Accounting Standards	Difference	IFRS
INCOME:			
Turnover	187.809	(39)	187.848
Cost of sales	(150.630)	(1.180)	(149.450)
Gross profit	37.179	(1.219)	38.398
Administrative and distribution expenses	(21.589)	5.218	(26.807)
Other income/ (expenses)	2.075	(510)	2.585
Financial income/(expenses)	(4.976)	(1.572)	(3.404)
Profit/(loss) from exchange differences			
Loss from investment in associates			
Extraordinary income/(expenses)	3.869	3.869	
Depreciation not charged to the operating cost	(2.250)	(2.250)	
PROFIT BEFORE TAXES	14.308	3.536	10.772
Income taxes		(2.348)	2.348
PROFIT FOR THE PERIOD	14.308	1.188	13.120
Attributable to:			
Equity holders of the parent company	11.856	114	11.742
Minority interest	2.452	1.073	1.379
	14.308	1.188	13.120

ATHENS MEDICAL CENTER S.A.



INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

ATHENS MEDICAL S.A.

APPENDIX I

RECONCILIATION OF THE FINANCIAL STATEMENTS BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

(All amounts are presented in thousands of Euro)

	Consolidated Income Statement at 30 th September 2004		
	Greek Accounting Standards	Difference	IFRS
INCOME:			
Turnover	137.726	0	137.726
Cost of sales	(109.290)	(765)	(108.525)
Gross profit	28.436	(765)	29.202
Administrative and distribution expenses	(15.880)	1.096	(16.976)
Other income/ (expenses)	1.543	(107)	1.650
Financial income/(expenses)	(4.379)	(382)	(3.997)
Profit/(loss) from exchange differences		0	0
Loss from investment in associates		0	0
Extraordinary income/(expenses)	(585)	(585)	0
Depreciations not charged to the operating cost	(1.688)	(1.688)	0
PROFIT BEFORE TAXES	7.447	(2.431)	9.878
Income taxes	0	3.607	(3.607)
PROFIT FOR THE PERIOD	7.447	1.176	6.271
Attributable to:			
Equity holders of the parent company	5.664	532	5.132
Minority interest	1.783	644	1.139
	7.447	1.176	6.271

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

APPENDIX I

RECONCILIATION OF EQUITY BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

**ADJUSTMENT TABLE OF EQUITY OF PERIOD BEGINNING (01/01/2005 AND 01/01/2004 RESPECTIVELY)
BETWEEN GREEK ACCOUNTING STANDARDS (G.A.S.) AND INTERNATIONAL ACCOUNTING
STANDARDS (I.A.S.)**

	<u>THE</u> <u>GROUP</u>		<u>THE COMPANY</u>	
	<u>31/12/2004</u>	<u>1/1/2004</u>	<u>31/12/2004</u>	<u>1/1/2004</u>
(The amounts are presented in thousands of Euro)				
Total equity, as presented according to G.A.S.	123.528	117.785	115.459	110.298
Adjustments				
Deletion of intangible assets which are not recognized	(13.670)	(17.968)	(12.159)	(16.461)
Valuation of fixed assets at fair value and differences due to depreciation rates	66.429	68.385	56.428	58.384
Provision for retirement indemnities	(8.781)	(7.326)	(8.781)	(7.326)
Provision/allowance for doubtful accounts	(3.200)	(2.350)	(3.200)	(2.350)
Transfer of payable dividends' recognition in their approval time by the G.A.	2.520	(672)	2.520	0
Reversal of fixed assets' valuation adjustment, according to L.2065	(502)	0	(502)	0
Accounting of leases	5.502	3.146	5.169	2.710
Reversal of real estate lease back gain	(5.013)	0	(5.013)	0
Effect due to investment measurement/valuation	(796)	(1.392)	711	89
Impairment of investments in subsidiaries	(1)		(1.039)	(1.039)
Recognition of deferred taxation	(9.254)	(15.428)	(6.799)	(11.922)
Transfer of government grants to deferred income	(73)	0	(73)	0
Impairment of assets	(2)	(1.250)		
Total adjustments	31.912	25.145	27.262	22.085
Invested capitals according to International Accounting Standards	155.440	142.930	142.721	132.383

- (1) Within the 2nd quarter of 2005 the Company recognized in its stand alone balance sheet the accumulated impairment losses concerning investments in subsidiaries and associates by adopting the relative provisions of IAS 27, in relation to measurement method in the stand alone balance sheet for investments in subsidiaries and associates (acquisition cost less impairment losses). The correction that took place was conducted in accordance with the provisions of IAS 8 "Accounting policies, changes in accounting estimates and errors", that is with retroactive correction of previous period's/year's accounts. The accumulated effect of the adjustments concerning years before January the 1st 2004 was recognized against the retained earnings at the above-mentioned date, while the corrections, concerning periods/fiscal years included in the accompanying financial statements were made in the respective periods/fiscal years. Hence, stand alone balance sheets of January the 1st and of December the 31st 2004 are presented adjusted in relation to those included in the financial statements issued for the 1st quarter of 2005. The effect of the above corrections was that the Equity included in the accompanying stand alone balance sheets for January the 1st and December the 31st 2004 is presented decreased by €1.039 respectively in relation to those presented in the issued financial statements of the 1st quarter of 2005.
- (2) Within the 2nd quarter of 2005, the Group's subsidiary Ortelia Holding Ltd recognized impairment loss on its fixed asset (helicopter) due to the fact that it did not recognize any depreciation for the years since the acquisition date until the transition date. The loss that arose came to the amount of €1.250 and it was recognized in the retained earnings at the transition date. Due to this impairment loss, the balance of the fixed asset was adjusted to its fair value, which is estimated to require no further correction. Thus, the consolidated balance sheets of January 1st and December 31st 2004 are presented adjusted in relation to those included in the financial statements issued for the 1st quarter of 2005. The consolidated Equity included in the accompanying stand alone balance sheets for January the 1st and December 31st 2004 are presented decreased by €1.250 respectively in relation to those presented in the issued financial statements of the 1st quarter of 2005.

INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

APPENDIX I

RECONCILIATION OF RESULTS BETWEEN GREEK ACCOUNTING STANDARDS AND IFRS

(All amounts are presented in thousands of Euro)

	<u>THE GROUP</u>	<u>THE COMPANY</u>
	<u>30-Sep-04</u>	<u>30-Sep-04</u>
Period's profits, as presented according to GAS	7.447	3.742
Adjustments:		
Taxes of previous years recognized directly in Equity	(175)	
Effect due to the de-recognition of intangible assets (Amortization write off in accounting books)	4.321	4.293
Depreciation of tangible fixed assets according to their useful lives	(1.006)	(1.006)
Provision for retirement indemnities	(1.091)	(1.091)
Provision for income tax over the period's profits	(2.240)	(975)
Effect of deferred taxation	(1.193)	(1.136)
Income from investments	(949)	
Provision/allowance for doubtful accounts	(638)	(638)
Accounting of leases	1.814	1.687
Other provisions	(19)	
Total adjustments	6.271	4.876
Period's profits according to International Accounting Standards		



ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005
 (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)
APPENDIX II

COMPANY'S SUBSIDIARIES AND TAX UNAUDITED YEARS PER COMPANY

Company's name	Company's location country	Activity	Participation (%)	Tax audited years
IATRIKI TECHNIKI S.A.	GREECE	Sale of Medical Tools & Sanitary/Health Equipment	56,00%	2003-2004
EREVNA S.A.	GREECE	Diagnostic & Therapeutic Center	51,00%	2003-2004
AXONIKI EREVNA S.A.	GREECE	Diagnostic Center	50,50%	2003-2004
PHYSIOTHERAPY AND SPORTS INJURY TREATMENT CENTER S.A..	GREECE	Physiotherapy & Sport Injury Restoration/Treatment Services	33,00%	2003-2004
HOSPITAL AFFILIATES INTERNATIONAL	GREECE	Organization & Administration of Hospitals and Clinics.	68,89%	2001-2004
MEDSANA BMC	ROMANIA	Diagnostic Center	100,00%	1997-2004
MEDSANA SRL	ROMANIA	Diagnostic Center	78,90%	1997-2004
EUROSITE HEALTH SERVICES S.A.	GREECE	Establishment & Operation of Hospitals and Clinics	100,00%	2003-2004
ORTELIA HOLDINGS	CYPRUS	Establishment, Organization & Operation of Hospitals and Clinics	99,99%	1998-2004

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS OF 30TH SEPTEMBER 2005
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

